Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity

BACKGROUND: Immune-stimulatory agents, like agonists of the innate immune receptor RIG-I, are currently tested in clinical trials as an intratumoral treatment option for patients with unresectable melanoma, aiming to enhance anti-tumor T cell responses. Switching of melanoma toward a dedifferentiate...

Descripción completa

Detalles Bibliográficos
Autores principales: Thier, Beatrice, Zhao, Fang, Stupia, Simone, Brüggemann, Alicia, Koch, Johannes, Schulze, Nina, Horn, Susanne, Coch, Christoph, Hartmann, Gunther, Sucker, Antje, Schadendorf, Dirk, Paschen, Annette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196182/
https://www.ncbi.nlm.nih.gov/pubmed/35697379
http://dx.doi.org/10.1136/jitc-2021-003863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196182/
https://www.ncbi.nlm.nih.gov/pubmed/35697379
http://dx.doi.org/10.1136/jitc-2021-003863

Ejemplares similares